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INTRODUCTION 
  
ANATOMY OF SHOULDER JOINT: 
  A normal shoulder is a highly mobile diarthrodial (synovial), ball and socket 
joint with a remarkable range of movement.1 Normal function of the shoulder complex 
requires the coordinated movements of the sternoclavicular (SC), acromioclavicular 
(AC), and glenohumeral (GH) joints, as well as the scapulothoracic articulation and the 
motion interface between the rotator cuff and the overlying coracoacromial arch. 
 Approximately 10% of the general adult population will experience an episode of 
shoulder pain in their lifetime2 pain in the shoulder is exceeded only by pain in the low 
back and the neck3 shoulder pain is a common reason for care seeking as it impacts upon 
on a range of activities of daily living, including sleep. It is estimated that around 95% of 
people with shoulder pain are treated in primary care settings4. 
 Many people presenting with acute shoulder pain are likely to have conditions 
that will resolve spontaneously regardless of treatment. Indeed, there are reports that 50% 
of people with shoulder pain do not seek care at all. Van der Windt DA et al5 reported 
that 23% of all new episodes of shoulder pain resolve fully within one month and 44% 
resolve within three months of onset. However, the results of studies on the natural 
history of shoulder pain vary considerably because of the range of definitions used to 
describe shoulder disorders.  
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 In these guidelines, the term ‘acute’ is defined as pain that has been present for 
less than three months; it does not refer to the severity or quality of pain. Chronic pain is 
pain that has been present for at least three months6  
 There is no universal definition of shoulder pain. For the purposes of these 
guidelines, ‘shoulder’ refers to the articulations of the scapula, clavicle and humerus 
together with the ligaments, tendons, muscles and other soft tissues with a functional 
relationship to these structures. 
 The articular surfaces consist of proximally the glenoid cavity of the scapula and 
distally the rounded head of the humerus. 
 The capsule consists of relatively loose connective tissue with a surface area more 
than twice that of the humeral head. Rotator cuff tendons and glenohumeral ligaments 
support the capsule from above and from the side. Below, the capsule has no support and 
forms a lax fold with a potential space, the inferior recess.7  
 The blood supply to the joint is from the anterior & posterior circumflex humeral 
arteries and the subscapular & suprascapular arteries. The innervations of this joint are 
from the musculocutaneous nerve, axillary nerve and the suprascapular nerve. 
 The movements of the shoulder joint is controlled by the spinal cord segments 
namely; C5 & C6 controls flexion, abduction and lateral rotation, C6, C7 & C8 controls 
extension adduction and medial rotation.  
SHOULDER PAIN: 
 Shoulder pain is common in the community; affecting 15–30% of adults at any 
one time.8 Causes include trauma, degenerative disease affecting the glenohumeral and 
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acromioclavicular joints and supporting soft tissue structures, and inflammatory diseases 
such as rheumatoid arthritis (RA), seronegative spondyloarthropathies, and crystal 
arthropathies, vascular diseases and may also be referred from the hand, neck, or viscera.9 
In one survey of patients with RA, shoulder pain affected 40% of patients early in the 
disease and the majority eventually had shoulder pain.10 The resultant pain and loss of 
function is also a major cause of disability in people with these conditions, particularly in 
the elderly.11 Evidence for the efficacy of various treatments of shoulder pain is 
limited.12,13,14 Most studies of interventions are of questionable quality and frequently 
lack outcome data relating to disability. There is little evidence to support or refute the 
efficacy of common interventions for shoulder pain. From a clinician’s perspective, 
therapeutic options for the management of this problem are limited. Simple analgesia, 
non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular steroid injection, and 
surgery all have their limitations, particularly in older populations with comorbidities. 
Although there are still many treatment modalities aiming at increasing the range of 
motion (ROM), relieving pain and as a result improving disability, the results reported 
about their effectiveness are inconsistent.15 
SUPRASCAPULAR NERVE: 
 The suprascapular nerve arises from the superior trunk of the brachial plexus at 
Erb’s point (C5 & C6) and runs an oblique course through the posterior cervical triangle 
toward the suprascapular notch, where it arrives together with the suprascapular vein and 
artery.  
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 The suprascapular nerve enters the suprascapular fossa beneath the superior 
transverse scapular ligament, while the artery and vein travel above the ligament and 
laterally in relation to the nerve.  
 From its origin at the brachial plexus, the suprascapular nerve runs as a mixed 
motor and sensory peripheral nerve toward the suprascapular notch, where it passes 
underneath the superior transverse ligament. Here, the suprascapular nerve releases a 
motor branch that usually innervates the supraspinatus muscle with two branches. The 
suprascapular nerve then travels around the lateral margin of the base of the scapular 
spine, passing the spinoglenoid notch, and enters the infraspinatus fossa.  
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                       STL – Superior Transverse Ligament  
SUP N – Suprascapular Nerve 
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At the spinoglenoid notch the nerve may be covered with the spinoglenoid ligament, also 
known as the inferior transverse scapular ligament. Thereafter, it divides into two, three 
or four motor branches innervating the infraspinatus muscle. All motor branches to the 
infraspinatus muscle are of the same length and diameter. The motor branches to the 
infraspinatus are significantly longer and slightly thicker than those to the supraspinatus. 
 The suprascapular nerve supplies sensory fibres to about 70% of the shoulder 
joint, including the superior and postero-superior regions of the shoulder joint and 
capsule,16 and the acromioclavicular joint. Suprascapular nerve block has shown some 
promise as an alternative treatment for patients with shoulder pain due to arthritis.18,19 A 
suprascapular nerve block in most studies consists of 10ml of 0.5% bupivacaine 
hydrochloride and 40 mg of methylprednisolone acetate (Depo-medrone). 
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REVIEW OF LITERATURE 
  Shanahan EM et al., 2003, has noted in his study that suprascapular nerve block 
is safe and efficacious treatment of shoulder pain associated with rheumatoid arthritis and 
degenerative shoulder conditions. 
 Asadolah S N et al., 2005, discussed in their study that 67% of patients were 
cured with only one session of suprascapular nerve block in the first week and 
accordingly there was no significant change in pain level between the first, fourth, or 
twelfth week after therapy, if patients follow the supplementary medical exercise and 
special health-care instructions. Therefore, concluded that if pain relief is obtained in the 
first week, it could last permanently unless other problems occur later. 
 M Ahern et al., 2002, concluded that Suprascapular nerve block is a safe and 
efficacious treatment for the treatment of shoulder pain in degenerative disease and/or 
arthritis. It improves pain, disability, and range of movement at the shoulder compared 
with placebo. It is a useful adjunct treatment for the practising clinician to assist in the 
management of a difficult and common clinical problem. Further, it may prove to be a 
useful treatment for patients who are unfit or unwilling to consider surgical intervention. 
 M Wetherall 2004, showed significant improvements in all pain scores and 
disability in the shoulders receiving both CT guided and anatomical landmark approach 
of the suprascapular nerve block, with no significant differences in the improvement in 
pain and disability between the two approaches at any time. Improvements in pain and 
disability scores were clinically and statistically significant. No significant adverse 
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effects occurred in either group. Patient satisfaction scores for pain relief using either 
approach were high. 
 M Smith et al., 2003, have demonstrated that suprascapular nerve block is 
efficacious without the need to image the area by ultrasound or fluoroscopy during the 
procedure. This study shows that this treatment not only reduces pain but also decreases 
disability and gives clinicians a proven efficacious treatment for patients with shoulder 
pain. Whether the efficacy would be further improved with guidance of the needle under 
direct imaging is unknown. The combination of nerve block with other approaches to 
pain relief would also be a potentially worthwhile area to study. 
 Sean P McCully et al., 2005, found that the suprascapular nerve block resulted in 
no significant changes in clavicular rotations and scapular posterior tilting. However, 
there was a significant increase in scapular external rotation and upward rotation. While 
kinematic changes returned to baseline within 25 min of the block, force measurements 
did not return to baseline until 75 min post-block. 
 Karatas and Meray 2002, have reported that nerve block close to the nerve with 
electromyography (EMG) guidance is more effective than blind injection in the 
suprascapular fossa. 
 Dominic Harmon and Conor Hearty 2007, stated that potential complications of 
suprascapular nerve block may be avoided through the use of ultrasound guidance and 
that pneumothorax has been reported following the procedure. They postulated that 
avoiding entering the suprascapular notch in the vertical plane will decrease the risk. 
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 Hossein Khatibi et al., 2005, stated that trigger point injections and suprascapular 
nerve block (SSNB) are advocated to break down the pain phenomenon and ease 
exercise. 
 Van der Heijden 1999, has denoted that approximately 10% of the general adult 
population will experience an episode of shoulder pain in their lifetime pain in the 
shoulder is exceeded only by pain in the low back and the neck shoulder pain is a 
common reason for care seeking as it impacts upon on a range of activities of daily 
living, including sleep. 
 Van der Windt DA et al., 1996, reported that 23% of all new episodes of shoulder 
pain resolve fully within one month and 44% resolve within three months of onset. 
However, the results of studies on the natural history of shoulder pain vary considerably 
because of the range of definitions used to describe shoulder disorders 
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METHODOLOGY 
STUDY DESIGN: 
 The design used in this study is double blinded randomised controlled trail.  
STUDY SETTING: 
 This study was conducted in Department of Physical Medicine and Rehabilitation, 
Directorate of Health & Family Welfare Services, Government of Puducherry. 
STUDY POPULATION: 
 The population of this study included patients with shoulder pain in the age group 
of 30 to 60 yrs. 
SAMPLE SIZE: 
 The total number of participants in this study was n=20. 
SELECTION CRITERIA: 
• Pain in the shoulder- due to local causes and referred pains are excluded. 
• Age group- 30 to 60yrs. 
• Pain due to trauma without fracture and dislocations. 
• Post traumatic stiffness and Degenerative shoulder pain. 
• Pain due to soft tissue of the shoulder like Adhesive Capsulitis. 
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MATERIALS: 
• Shoulder Pain and Disability Index (SPADI): 
                            The SPADI is a self-administered questionnaire that consists of two 
dimensions, one for pain and the other for functional activities. The pain dimension 
consists of five questions regarding the severity of an individual's pain. Functional 
activities are assessed with eight questions designed to measure the degree of difficulty 
an individual has with various activities of daily living that require upper-extremity use. 
It takes 5 to 10 minutes for a patient to complete and is the only reliable and valid region-
specific measure for the shoulder. To answer the questions, patients place a mark on a 
10cm visual analogue scale for each question. Verbal anchors for the pain dimension are 
‘no pain at all’ and ‘worst pain imaginable’, and those for the functional activities are ‘no 
difficulty’ and ‘so difficult it required help’. The scores from both dimensions are 
averaged to derive a total score. It shows good internal consistency, test-retest reliability, 
and criterion and construct validity. It can detect change over time and accurately 
discriminates between patients who have improved or worsened. 
• Drugs used:  
 Injection depometral 40 mg + locally acting anaesthetic agent- 
0.5% bupivivocane hydrochloride (or) 1% xylocaine. 
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PROCEDURE: 
 Patients were recruited conveniently from the Department of Physical Medicine 
and Rehabilitation, Puducherry. All the participants were interviewed and examined to 
ensure that the selection criteria were fulfilled. Patients took part in the study after 
informed consent had been obtained and the procedure has been explained. The rights 
and privacy of the participants were protected at all times. The participants were grouped 
into two. Group A received Suprascapular Nerve Block and Exercises. Group B received 
Heat modalities and Exercises. 
RANDOMIZATION: 
 Following completion of all pre-intervention assessments, participants were 
randomly assigned to one of the two groups Experimental group & Control (Placebo) 
Group via a computer generated random number sequence. 
PREPARATION: 
 All the participants underwent a set of investigation procedures like Hb, T.C, D.C, 
ESR, X-ray, MRI Scan, Blood sugar and ECG. They were given the Shoulder Pain and 
Disability Index (SPADI) questionnaire and instructed to place a mark on the line that 
best represents their experience during the last week attributable to their shoulder 
problems. 
 The participants were tested initially for any allergic reaction of the local 
anaesthetic. The procedure is done bedside. The affected side shoulder and scapular 
region is cleaned and prepared for the preocedure. The site of injection is covered with a 
central hole towel. 
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IDENTIFICATION OF THE INJECTION SITE: 
 Draw a line from the base of the neck to the posterior axillary fold and another 
line over the spine of the scapula i.e, tip of the acromian to D4 verterba spine (exactly 
over the spine of scapula). Where these two line crosses is the point of injection. 
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 The active treatment required an 11 ml injection into the suprascapular fossa with 
10 ml of 0.5% bupivacaine and 40 mg of methylprednisolone after a subcutaneous 
injection of 1% lidocaine (lignocaine) for local analgesia.14  
 The needle was directed over the spine in the plane of the scapula and advanced 
to the hub of the needle or until contact was made with the floor of the suprascapular 
fossa. After attempted aspiration, the agent was slowly injected to fill the fascial contents 
of this fossa to produce an indirect suprascapular nerve block. At this point the 
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suprascapular nerve gives off branches to supply the glenohumeral joint, the 
acromioclavicular joint, and the supraspinatus muscle. 
 The placebo injection consisted of 5 ml normal saline infiltrated subcutaneously 
after the 2 ml subcutaneous 1% lidocaine infiltration. The use of a subcutaneous injection 
as placebo,well away from the suprascapular nerve,was thought to be important because 
of the theoretical possibility of saline itself being potentially active in providing some 
degree of nerve blockade. The injections were performed out of the line of vision of the 
patients. They were all performed by a single operator who did not see the patients during 
the follow up period. The patient assessor was unaware of the nature of the injection. To 
check whether the blinding was effective, immediately after the injection patients and 
assessors were separately asked to guess which injection the patient had received. The 
results of this assessment confirmed the adequacy of the blinding for the patient and the 
assessor. 
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DATA ANALYSIS & RESULTS 
Table-1 
Outcome values of Shoulder Pain and Disability Index (SPADI) in Group-A at baseline 
(Pretest), 5 days post-intervention (Post 1) and 10 days post-intervention (Post 2). 
 
 
SPADI  Group ‐ A  Group ‐ B 
Sl  Pre  Post 1  Post 2  Pre  Post 1  Post 2 
1  85.1    14.6    12.3    81.2    40.5    24.6 
2  87.1    20.0    12.1    85.1    48.7    21.1 
3  84.6    8.1    7.5    83.8    44.8    19.1 
4  83.8    5.0    4.0    87.1    49.7    20.1 
5  83.8    5.0    4.0    85.1    47.7    24.6 
6  84.8    8.1    8.1    78.0    38.5    16.0 
7  81.2    5.0    4.0    84.8    44.3    21.1 
8  78.0    5.0    4.0    84.6    46.8    16.0 
9  83.8    6.8    6.8    83.2    42.2    19.0 
10  87.1    18.7    14.6    81.2    44.8    21.1 
MEAN  83.93    9.630    7.740    83.41    44.80    20.27 
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WITHIN GROUP ANALYSIS 
Table – 2 
ANALYSIS OF IMPROVEMENT IN SPADI 
Sl. No  Group Analysis Mean ± SD “t” value Significance 
 
1 
 
A 
Pre test 
83.93±2.694 
54.91 
 
P > 0.05 
Post test 1 9.630±5.897 
 
2 
 
B 
Pre test 83.41±2.623  
69.28 
 
P > 0.05 
Post test 1 44.8±2.603 
 
The results of this study from the above table indicate that, in Within Group analyses of 
Improvement in Shoulder Pain And Disability Index(SPADI) shows that extremely significant in 
individuals of both Group A & Group B. 
Figure - 1 
ANALYSIS OF IMPROVEMENT IN SPADI 
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Table - 3 
ANALYSIS OF RETENTION OF SPADI  
Sl. No  Group Analysis Mean ± SD “t” value Significance 
 
1 
 
A 
Post test 1 9.630±5.897  
2.459 
 
P > 0.05 
Post test 2 7.740±3.998 
 
2 
 
B 
Post test 1 44.80±3.603  
18.36 
 
P > 0.05 
Post test 2 20.27±2.964 
 
The results of this study from the above table indicate that, in Within Group analyses of Retention 
in Shoulder Pain And Disability Index(SPADI) shows that extremely significant in individuals of 
both Group A & Group B. 
Figure - 2 
ANALYSIS OF RETENTION OF SPADI  
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BETWEEN GROUP ANALYSIS 
Table – 4 
ANALYSIS OF DIFFERENCE IN SPADI  
  
Sl. No  Group Mean ± SD Mean Difference “t” value Significance 
1 A 9.630 ± 1.865  
35.17 ± 2.185 
 
16.09 
 
P > 0.05 2 B 44.80 ± 1.139 
 
The results of this study from the above table indicate that, in Between Group analyses of 
Shoulder Pain And Disability Index(SPADI) is significantly improved in the Group A individuals 
who receive Suprascapular nerve block than Group B. 
Figure – 3 
ANALYSIS OF DIFFERENCE IN SPADI  
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DISCUSSION 
 
 The results of this study show a clear benefit from the use of suprascapular nerve 
block using depometral and bupivivocane hydrochloride in patients with shoulder pain. 
There was a statistically and clinically significant reduction in pain. This benefit was 
prolonged, with benefit still present at 12 weeks. There were no significant side effects 
from the injection, which was well tolerated by most of the patients. 
 As suggested by Carette in a recent editorial20, we included a valid and 
reproducible measurement of disability as a primary end point measurement. There was 
also an overall modest, but clinically significant, improvement in disability as measured 
by the disability subscale of the SPADI. Although most of the patients had structurally 
very abnormal shoulders, a reduction in pain seems to have reduced the level of their 
measurable disability at the shoulder.  
 An improvement of 10 on the SPADI has been shown to represent significant 
clinical improvement. In this study about two thirds of the patients who received the 
active injection had at least this level of improvement at weeks 1 and 4. The percentage 
improvement decreased after this, but more than 50% of the subjects had clinical 
improvement over baseline at follow up as compared with less than 20% in the placebo 
group. Interestingly, while both pain and disability subscales improved significantly, the 
pain subscale improved more than the disability scale. This may be because many of the 
patients had structurally abnormal shoulders due to long duration of disease.  
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 As a result, the level of disability was not likely to show much improvement. The 
range of movement improvement was modest, with only abduction and the hand behind 
back combined movement showing any significant improvement.  
Values are mean scores and error bars are 95% confidence intervals. 
 
We have included all relevant clinical and radiological information on the patients in the 
study in order to describe the group as clearly as possible. Even the presentation of the 
data was difficult because of the lack of uniform clinical descriptors in shoulder studies, 
and the lack of valid and reliable scoring systems for radiological imaging of the 
shoulder.  
In general, our patients were elderly and had longstanding shoulder pain from 
degenerative and/or rheumatoid disease. The results suggest that suprascapular nerve 
block reduces pain and disability at the shoulder for patients with shoulder pain, 
irrespective of their clinical diagnosis. 
The low incidence of reported side effects is an advantage. In addition, the procedure is 
easy to learn and has a short “learning curve”. 
That pain relief from the block extends beyond the pharmacological effect of the drug is 
well described. There are a number of possible explanations for this: 
• Decreases in central sensitisation of dorsal horn nociceptive neurones or a “wind 
down” (because of a reduction of peripheral nociceptive input) have been 
suggested.  
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• A depletion of substance P and nerve growth factor in the synovium and afferent 
C fibres of the glenohumeral joint after the blockade may also contribute to the 
longer term relief.  
• It is also interesting to speculate on the potential contribution to pain relief from 
the direct infiltration of the supraspinatus muscle, and the possible blockade of 
those fibres of the nerve supplying the supraspinatus muscle and possible 
“downstream” blockade of the infraspinatus muscle. No reduction in the power of 
these muscles was reported, although this could not be formally tested because of 
the severity of the shoulder pathology in most of the patients studied. 
We have demonstrated that suprascapular nerve block is efficacious without the need to 
image the area by ultrasound or fluoroscopy during the procedure. This study shows that 
this treatment not only reduces pain but also decreases disability and gives clinicians a 
proven efficacious treatment for patients with shoulder pain. Whether the efficacy would 
be further improved with guidance of the needle under direct imaging is unknown. The 
combination of nerve block with other approaches to pain relief would also be a 
potentially worthwhile area to study. 
 
 In summary, this study provides evidence that suprascapular nerve block is a safe, 
effective, and well tolerated treatment for patients with shoulder pain. It can be 
performed in an outpatient department and provides the clinician with an alternative or 
additional approach to oral drug treatment and intra-articular injection. Further, it may 
prove to be a useful treatment for patients who are unfit or unwilling to consider surgical 
intervention. 
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CONCLUSION 
In this study, Group A individuals who depended purely on the Suprascapular Nerve 
Block and Exercises, showed a greater improvement than the Group B individuals who depended 
on Heat Modalities and Exercises, which suggests that the influence Suprascapular Nerve Block 
and Exercises are better in use clinical setting. 
 From this study it is concluded that Suprascapular Nerve Block and Exercises 
significantly improve the Shoulder Pain and Disabilities in individuals with Shoulder Pain.  
Hence, Suprascapular Nerve Block and Exercises can be implemented in the 
rehabilitation program of every individual with Shoulder Pain in order to reduce Pain and 
Disabilities. 
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